Pfizer enters the week with a curious split: the stock is quietly grinding higher, up 0.6% on the week to $25.70, yet short sellers have been adding positions at their fastest monthly pace in months.
Short interest is the standout tension right now. Bears have rebuilt their positions aggressively — SI hit 3.07% of the free float on June 9, up 9.1% on the week and up nearly 24% over the past month. That 30-day climb is meaningful: it puts short positioning at levels not seen since early May. The pace of accumulation accelerated sharply on June 8-9, adding roughly 9.4 million shares in a single session. Yet the borrow market tells a completely different story. Availability remains extraordinarily loose at over 4,200% — meaning there are more than 42 shares available to borrow for every one already shorted. Cost to borrow has actually fallen over the week, easing to just 0.36%, down from around 0.48% earlier in the month. This is not a squeezable short. Bears are adding with no friction, and the lending market is offering them every incentive to do so.
Options positioning, by contrast, offers little drama. The put/call ratio of 0.87 sits almost exactly on its 20-day average of 0.88, a z-score of -0.21 that flags no unusual directional lean. The PCR has drifted lower over the past month — it was running above 0.93 in mid-May — which means options traders are actually becoming defensive even as short sellers grow more bearish. That divergence is worth noting: the two positioning signals are not confirming each other.
The street picture is mixed but tilting cautious. The most recent analyst action landed this morning: RBC Capital upgraded PFE from Underperform to Sector Perform, though the firm's $25.00 price target sits below the current price — a lukewarm lift at best. Citigroup raised its target modestly to $27 in late April while keeping a Neutral rating. Morgan Stanley held Equal-Weight with a $28 target in early April. Against that defensive cluster, Guggenheim remains an outlier with a Buy and a $36 target, and CICC initiated coverage in April with an Outperform and a $33 target. The consensus lands at Hold with 16 holds and one underperform among rated analysts. The PE multiple of 8.8x and EV/EBITDA of 8.1x both reflect a stock the market is treating as a show-me story. Forward EPS momentum ranks in the 40th percentile on a 30-day basis, and in the 45th on 90 days — uninspiring. The one bright spot in the factor scores is the 12-month forward EPS year-on-year increase, which ranks in the 97th percentile, suggesting that if consensus estimates hold, there is earnings recovery priced in for the year ahead. The dividend yield score ranks in the 93rd percentile, a reminder that Pfizer's income credentials remain a floor for passive and income-oriented holders.
The institutional base is stable. BlackRock holds 8.7% of shares, State Street 5.3%, with Geode and Fisher among the other sizable positions. Fisher added a notable 53 million shares as of the last filing period — a significant incremental bet from a value-oriented manager. These are not short-term flows, but Fisher's positioning suggests at least one large active manager views current levels as attractive.
Recent earnings history offers limited signal: Q1 results on May 5 produced a modest +0.9% one-day move, followed by a -1.6% five-day drift. The prior print in late April produced a -2.0% one-day reaction. Small moves, consistent with a stock where the narrative is slow-moving rather than event-driven. The next quarterly report is scheduled for July 28 — watch whether the short rebuild ahead of that date accelerates, and whether the RBC upgrade prompts any covering in the near term.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
